Subjects:
Free Research Articles
Topics:
myelofibrosis
On page 2638 in the 23 October 2014 issue, there is an error in Table 1. In the “Phase” column, the entry for fedratinib (SAR302503), which reads “2 (withdrawn),” should read “3 (withdrawn).” The corrected table is shown below. The error has been corrected in the online version, which now differs from the print version.
Table 1
JAK inhibitors tested in clinical trials in MF
| Agent . | Other targets . | Phase . |
|---|---|---|
| Ruxolitinib | JAK1 | 3 (approved) |
| Fedratinib (SAR302503) | FLT3, RET | 3 (withdrawn) |
| Pacritinib (SB1518) | FLT3 | 3 |
| Momelotinib (CYT387) | JAK1, JNK1, TYK2, CDK2, RICJ2 | 3 |
| Lestaurtinib (CEP-701) | FLT3, TRKA | 2 (withdrawn) |
| AZD1480 | JAK1, JAK3, FLT4, FGFR1, TRKA | 2 |
| Gandotinib (LY2784544) | — | 1 (withdrawn) |
| XL019 | — | 1 (withdrawn) |
| NS-018 | SRC, FLT3, ABL | 1/2 |
| BMS-911543 | — | 1/2 (withdrawn) |
| Agent . | Other targets . | Phase . |
|---|---|---|
| Ruxolitinib | JAK1 | 3 (approved) |
| Fedratinib (SAR302503) | FLT3, RET | 3 (withdrawn) |
| Pacritinib (SB1518) | FLT3 | 3 |
| Momelotinib (CYT387) | JAK1, JNK1, TYK2, CDK2, RICJ2 | 3 |
| Lestaurtinib (CEP-701) | FLT3, TRKA | 2 (withdrawn) |
| AZD1480 | JAK1, JAK3, FLT4, FGFR1, TRKA | 2 |
| Gandotinib (LY2784544) | — | 1 (withdrawn) |
| XL019 | — | 1 (withdrawn) |
| NS-018 | SRC, FLT3, ABL | 1/2 |
| BMS-911543 | — | 1/2 (withdrawn) |
© 2015 by The American Society of Hematology
2015
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal